JAZZHealthcare · BiotechnologyThe 22 Wall Street analysts covering Jazz Pharmaceuticals Plc hold a median 12-month price target of $300 — +29.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 5 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Jazz Pharmaceuticals Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (73): Analysts have, on balance, been cutting their forecasts.
Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on JAZZ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +29.7% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2026 | Citigroup | Initiates | Buy | $325 |
| 24 Sept 2026 | Goldman Sachs | Reinstates | Buy | $337 |
| 11 Sept 2026 | UBS | Maintains | Buy | $315 → $337 |
| 11 Sept 2026 | UBS | Maintains | Buy | — |
| 10 Sept 2026 | Barclays | Maintains | Overweight | $270 → $271 |
| 10 Sept 2026 | Barclays | Maintains | Overweight | — |
| 26 Aug 2026 | Deutsche Bank | Maintains | Buy | — |
| 26 Aug 2026 | Deutsche Bank | Maintains | Buy | $287 → $300 |
| 26 Aug 2026 | Morgan Stanley | Maintains | Overweight | $283 → $322 |
| 26 Aug 2026 | Morgan Stanley | Maintains | Overweight | — |
| 26 Aug 2026 | Needham | Maintains | Buy | $292 → $310 |
| 26 Aug 2026 | Needham | Maintains | Buy | — |
| 26 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 26 Aug 2026 | Truist Securities | Maintains | Buy | $264 → $281 |
| 11 Aug 2026 | Morgan Stanley | Maintains | Overweight | $280 → $283 |
| 11 Aug 2026 | Morgan Stanley | Maintains | Overweight | — |
| 4 Aug 2026 | Baird | Maintains | Outperform | — |
| 4 Aug 2026 | Baird | Maintains | Outperform | $252 → $280 |
| 4 Aug 2026 | Barclays | Maintains | Overweight | $260 → $270 |
| 4 Aug 2026 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JAZZ appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 6 Oct 2026, Jazz Pharmaceuticals Plc returned +68.2% against +16.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 43% of US stocks
Cheaper than 36% of US stocks
Cheaper than 30% of US stocks
Cheaper than 41% of US stocks
Higher than 63% of US stocks
Higher than 53% of US stocks
Higher than 96% of US stocks
Higher than 85% of US stocks
Higher than 83% of US stocks
Higher than 83% of US stocks
Higher than 84% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Jazz Pharmaceuticals Plc has a market value of $15.3B and an enterprise value of $17.5B.
Revenue in the twelve months to 30 June 2026: $4.6B. The latest quarter grew 15.5% year on year.
Net income over the same four quarters: $940.8M, a 20.4% net margin.
Diluted earnings per share, trailing twelve months: $14.50.
Free cash flow in the twelve months to 30 June 2026: $1.3B.
Trailing P/E: 15.9×; forward P/E: 8.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Jazz Pharmaceuticals Plc employs 2,890 people — $1.6M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Jazz Pharmaceuticals Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights its Style Scores as a way for investors to find stocks rated highly according to their investing style. The excerpt says it will explain why Jazz Pharmaceuticals is considered a strong value stock.
Why it matters — The item presents Zacks' value-oriented perspective on JAZZ and its stock-rating framework.
Jazz Pharmaceuticals executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies, and business-development priorities during the Morgan Stanley Global Healthcare Conference. The company is targeting a $5 billion opportunity for zanidatamab as oncology revenue tops $1 billion.
Why it matters — A Jazz Pharmaceuticals watcher would care because the update provides insight into the company's oncology growth strategy, the commercial traction of its newly launched therapies, and its forward-looking business-development priorities.
Jazz Pharmaceuticals discussed development and commercial plans for its oncology, epilepsy, and sleep franchises with a Deutsche Bank analyst, highlighting expansion potential for the HER2-targeted therapy Ziihera and ongoing work on EPIDIOLEX. An unnamed Jazz executive reported a statistically significant overall-survival result for zanidatamab-plus-chemotherapy versus a control arm in a second interim analysis.
Why it matters — A shareholder would watch whether Ziihera's expanding opportunity and encouraging survival data could broaden Jazz's oncology pipeline and support future growth.
Jazz Pharmaceuticals acquired Actio Biosciences for $820 million upfront, with up to $500 million in additional milestone payments potentially due to Actio shareholders. The deal was announced as part of Jazz's corporate activity.
Why it matters — The acquisition represents a significant capital outlay for Jazz and could expand its pipeline, making the financial terms and the deal's strategic fit relevant for Jazz investors.
Jazz Pharmaceuticals plc presented at the Deutsche Bank 2026 Healthcare Summit, and a transcript of the presentation was published via Seeking Alpha. The item indicates the company took part in the conference's investor-event programming.
Why it matters — A JAZZ watcher would care because conference presentations and transcripts offer insight into how the company communicates its business with the investment community.
The 22 Wall Street analysts covering Jazz Pharmaceuticals Plc have a median 12-month price target of $300, with estimates ranging from $225 to $337. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 22 analysts covering Jazz Pharmaceuticals Plc, 20 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jazz Pharmaceuticals Plc 99 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Oct 2026, Jazz Pharmaceuticals Plc ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 22 analysts implies +29.7% from the last close, and Ticker Nerd's factor model ranks Jazz Pharmaceuticals Plc 99 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Jazz Pharmaceuticals Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JAZZ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $225 to $337 over the next 12 months.
Jazz Pharmaceuticals Plc returned +68.2% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious and often underserved conditions. Its portfolio includes treatments for sleep disorders, epilepsy, oncology, and other specialized therapeutic areas, with products such as Xywav, Epidiolex, Zepzelca, Rylaze, and Vyxeos supporting patients who may have limited treatment options.
The most recent item we track (Zacks Investment Research, 6 Oct 2026): "Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock". Zacks Investment Research highlights its Style Scores as a way for investors to find stocks rated highly according to their investing style. The excerpt says it will explain why Jazz Pharmaceuticals is considered a strong value stock.
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious and often underserved conditions. Its portfolio includes treatments for sleep disorders, epilepsy, oncology, and other specialized therapeutic areas, with products such as Xywav, Epidiolex, Zepzelca, Rylaze, and Vyxeos supporting patients who may have limited treatment options. Jazz Pharmaceuticals plc works across the United States, Europe, and other international markets, serving healthcare providers, hospitals, and patients through prescription medicines and specialty care solutions. The company emphasizes rare disease and oncology medicines, making it an important participant in the global specialty pharmaceutical market. Headquartered in Dublin, Ireland, Jazz Pharmaceuticals plc maintains a focused business model centered on identifying, developing, and commercializing targeted therapies for complex medical needs.
CEO Ms. Renee D. Gala · 2,890 employees · Ireland · https://www.jazzpharma.com
